<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ADD8049D-3CA3-403E-907C-BCCAA6D666BC"><gtr:id>ADD8049D-3CA3-403E-907C-BCCAA6D666BC</gtr:id><gtr:firstName>Lars</gtr:firstName><gtr:surname>Fugger</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800500"><gtr:id>7E66A33F-5F86-4CED-AEDF-BCBDA7439368</gtr:id><gtr:title>Multiple sclerosis and the HLA region. Functional genetics.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800500</gtr:grantReference><gtr:abstractText>Multiple sclerosis (MS) is a neurological disease, which often affects young women. There is no effective treatment for MS. To develop new drugs it is necessary to understand in detail what kind of disease MS is. 
It has been known for many year that there is a strong genetic component in MS, and there have been many attempts to identify the actual genes that predispose to the disease.
We will study a number of genes that play roles in the immune-response to shed light on which part of the immunesystem that contribute to the development of MS.</gtr:abstractText><gtr:technicalSummary>The HLA region stands out as the only known major risk region for MS, and it is important to identify exactly which HLA genes confer susceptibility and how they do so. Even though there are data to suggest that the HLA class II locus DR is the single strongest genetic factor influencing susceptibility to MS, there are new data to suggest that genes in the HLA class I region also play a role in the development of MS. The exact identity of these genes, their potential interaction with each other and the already identified HLA class II risk gene(s), are not well understood. Likewise it is still unclear how the HLA genes actually influence the susceptibility to MS. 

A systematic dissection of how the HLA region predisposes to MS provides the best handle to get a grip on the genetic complexity that characterizes MS. Only by understanding this complexity will it be possible to get a coherent understanding of the disease pathways. This will allow for the development of new drugs that are more effective and with fewer side effects than the ones that are currently in use.

The aim of this project is to investigate in a functional manner to what extent and how HLA class I genes predispose to/protect against MS and how they interact with MS associated HLA class II genes.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>844248</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>A 2.4 minutes animation of how a gene confers risk to multiple sclerosis</gtr:description><gtr:id>17FA39E5-5787-45F1-A635-83EA6BF451E8</gtr:id><gtr:impact>Convey the message to professionals and laypersons in an understandable manner</gtr:impact><gtr:outcomeId>54621d04d27a96.16435248</gtr:outcomeId><gtr:title>How a gene confers risk to multiple sclerosis</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>TV programme</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57A55981-6609-4DAB-A66F-9051AF4D4BDD</gtr:id><gtr:impact>TV programme

Public awareness of our research</gtr:impact><gtr:outcomeId>35F027EF878</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting with MS patients and their families</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5A08ED78-B18C-445D-BAEF-A1B5C2B4080C</gtr:id><gtr:impact>better understanding of MS and how it is being treated now and in the future

Positive feedback</gtr:impact><gtr:outcomeId>5462190704b804.16981161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Science Europe</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>7559F63E-A112-4867-921E-C8CD331CEA5D</gtr:id><gtr:impact>Vivi section and access to big data</gtr:impact><gtr:outcomeId>54621a2737ffa3.45122168</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3B2417BD-3A7C-4480-836F-803CBB137B42</gtr:id><gtr:title>Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbd5fc47723096b3e0f2a3c6fbdc73b2"><gtr:id>fbd5fc47723096b3e0f2a3c6fbdc73b2</gtr:id><gtr:otherNames>McMahon RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>pm_13706_26_21543847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8685368-DFC3-4248-A459-90B2D2BA2445</gtr:id><gtr:title>From genes to function: the next challenge to understanding multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfd30e9e606c194dffc5c461b84c98d6"><gtr:id>dfd30e9e606c194dffc5c461b84c98d6</gtr:id><gtr:otherNames>Fugger L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>SyV9w4RThWC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D572334-198C-479C-9533-FC099C03E5DA</gtr:id><gtr:title>Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba5b17335e2433f6a3cc1adbc6b7ccc9"><gtr:id>ba5b17335e2433f6a3cc1adbc6b7ccc9</gtr:id><gtr:otherNames>Rigaud S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13706_26_21543760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99A4690D-CBFB-4EB6-A791-E17B7CCAE560</gtr:id><gtr:title>Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dae4a004efebd5e873710e47bdf13ae"><gtr:id>9dae4a004efebd5e873710e47bdf13ae</gtr:id><gtr:otherNames>Arun T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13706_26_23365093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E08F9DF6-4673-48DB-B511-6170CCACFB8A</gtr:id><gtr:title>Activation of central orexin/hypocretin neurons by dietary amino acids.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85ab7ae90ffc6693df7e319a7c636ef7"><gtr:id>85ab7ae90ffc6693df7e319a7c636ef7</gtr:id><gtr:otherNames>Karnani MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_13706_26_22099463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDC5C62B-1E71-418F-AEAD-2356FF540526</gtr:id><gtr:title>Pathogenic CD8(+) T cells in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a77fb0f2314c03a96d151763fa8313dc"><gtr:id>a77fb0f2314c03a96d151763fa8313dc</gtr:id><gtr:otherNames>Friese MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>P8jMkm2CWp3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>874BDBEF-384E-4EE2-8446-883830064F14</gtr:id><gtr:title>Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/850b9ea43c070c32110c02bbfd847b01"><gtr:id>850b9ea43c070c32110c02bbfd847b01</gtr:id><gtr:otherNames>Du Pr? MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_13706_26_21683079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A0636FB-D2E6-4AF3-8036-3DB9AABEB422</gtr:id><gtr:title>Constitutively active Lck kinase in T cells drives antigen receptor signal transduction.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1acd48b435d6ed60d479e0726c769f"><gtr:id>ff1acd48b435d6ed60d479e0726c769f</gtr:id><gtr:otherNames>Nika K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>JDegt5MmNvL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF83E968-D150-4D95-95D7-C6FEB658A8B0</gtr:id><gtr:title>Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7271d887d655ab8bf8e880119ff2237"><gtr:id>a7271d887d655ab8bf8e880119ff2237</gtr:id><gtr:otherNames>Tenzer S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>CwnEMqQznKb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33CEDAAA-F815-425E-A635-C25EEEE9375E</gtr:id><gtr:title>Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a77fb0f2314c03a96d151763fa8313dc"><gtr:id>a77fb0f2314c03a96d151763fa8313dc</gtr:id><gtr:otherNames>Friese MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>DX3xafEEBwa</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800500</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>